Publications by authors named "Jonathan A Ledermann"

Claim this Profile
T
The PARP inhibitor/Immunotherapy Paradox in Advanced Ovarian Cancer: Positive Endpoints, Perplexing Interpretations.
Jonathan A Ledermann, Robert L Coleman

Ann Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.
Stamatios Petousis, Ilker Kahramanoglu, Christian Appenzeller-Herzog, Martina A Angeles, Chrysoula Margioula-Siarkou, Jonathan A Ledermann

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.
Uma A Mukherjee, Rowan E Miller, Jonathan A Ledermann

Ther Adv Med Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, Sven Mahner, Andrés Redondo, Jonathan A Ledermann

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, Domenica Lorusso, Ursula A Matulonis, Jonathan A Ledermann

Gynecol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Katherine Elizabeth Francis, Sandy Simon, Val Gebski, Florence Joly, Jonathan A Ledermann

Gynecol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.
Sharon H Nahm, Belinda E Kiely, Rachel L O'Connell, Yeh Chen Lee, Alison Davis, Jonathan A Ledermann

Int J Gynecol Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
Mary McCormack, Gemma Eminowicz, Dolores Gallardo, Patricia Diez, Laura Farrelly, Jonathan Andrew Ledermann

Lancet· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London.
Karim H El-Shakankery, Joanna Kefas, Kieran Palmer, Andrew Houston, Uma Mukherjee, Jonathan A Ledermann

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Felicia Roncolato, Madeleine T King, Rachel L O'Connell, Yeh Chen Lee, Florence Joly, Jonathan A Ledermann

Gynecol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
Angelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, Robert L Coleman, Mansoor R Mirza

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEK 1 inhibition and bleeding in hereditary haemorrhagic telangiectasia.
Claire L Shovlin, Dilip Patel, Adrianna Bielowka, Jonathan A Ledermann, Atieh Modarresi

Br J Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Rebecca C Arend, Bradley J Monk, Ronnie Shapira-Frommer, Ashley F Haggerty, Edwin A Alvarez, Jonathan A Ledermann

J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention.
Ellen Nuttall Musson, Rowan E Miller, Marc R Mansour, Michelle Lockley, Jonathan A Ledermann

Leukemia· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, Alla S Lisyanskaya, Sandro Pignata

Gynecol Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
Marc P Bonaca, Javid J Moslehi, Jonathan A Ledermann, Elisabete Michelon, Caimiao Wei

Oncologist· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-supervised deep learning for highly efficient spatial immunophenotyping.
Hanyun Zhang, Khalid AbdulJabbar, Tami Grunewald, Ayse U Akarca, Yeman Hagos, Jonathan A Ledermann

EBioMedicine· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Robert D Morgan, Andrew R Clamp, Bethany M Barnes, Kirsten Timms, Helene Schlecht, Jonathan A Ledermann

Int J Gynecol Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
John Devin Peipert, Sandra Goble, Jeff Isaacson, Xiaodan Tang, Katrine Wallace, Jonathan A Ledermann

Gynecol Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".
David M O'Malley, Jonathan A Ledermann, Robert L Coleman

Gynecol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
David M O'Malley, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Jonathan A Ledermann

Gynecol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
C Blake Gilks, Christina I Selinger, Ben Davidson, Martin Köbel, Jonathan A Ledermann

Int J Gynecol Pathol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
Rowan E Miller, Osnat Elyashiv, Karim H El-Shakankery, Jonathan A Ledermann

Onco Targets Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer.
Michael J Flynn, Jonathan A Ledermann

Cancer Drug Resist· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis